<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35290880</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3360</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>140</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Psychoneuroendocrinology</Title>
          <ISOAbbreviation>Psychoneuroendocrinology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Young adult Swedish patients with autoimmune Addison's disease report difficulties with executive functions in daily life despite overall good cognitive performance.</ArticleTitle>
        <Pagination>
          <StartPage>105714</StartPage>
          <MedlinePgn>105714</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psyneuen.2022.105714</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0306-4530(22)00055-5</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES">Sub-optimal replacement of glucocorticoids (GC) in autoimmune Addison's disease (AAD) may affect cognitive functioning. The present study therefore sought to investigate cognitive performance and self-reported problems with executive functions in a cohort of young adult patients with AAD.</AbstractText>
          <AbstractText Label="DESIGN AND METHODS">67 patients with AAD (39 females), mean age 32 yrs. (range 19-41), and 80 control participants (43 females), mean age 29 yrs. (range 19-43), completed neuropsychological tests estimating verbal and non-verbal intellectual ability, learning, memory and executive functioning, in addition to self-report scales assessing problems with executive functions, fatigue and symptoms of anxiety and depression.</AbstractText>
          <AbstractText Label="RESULTS">Patients performed within the average range on all cognitive tests compared to population norms. However, female AAD patients reported more problems than controls with both hot (emotion regulation) and cold (cognitive regulation) executive functions in daily life. Moreover, experienced problems with executive functions in both male and female patients were associated with increased mental fatigue and lower GC replacement doses.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Despite average performance in neuropsychological tests by both sexes, young adult female patients with AAD experience problems with executive functions in daily life. Coping with mental fatigue and optimization of pharmacotherapy may be important factors to be addressed in order to provide timely support for patients. Future research is needed to further determine other risk factors for experiencing executive function impairments in AAD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Van't Westeinde</LastName>
            <ForeName>Annelies</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Women's and Children's Health, Karolinska Institutet, Pediatric Endocrinology Unit, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ström</LastName>
            <ForeName>Sara</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet and Department of Endocrinology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hirvikoski</LastName>
            <ForeName>Tatja</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Women's and Children's Health, Pediatric Neuropsychiatry Unit, Center for Neurodevelopmental Disorders at Karolinska Institutet (KIND), Karolinska Institutet, SE-17177 Stockholm Sweden; Unit for Habilitation &amp; Health, Stockholm County Council, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Dahlqvist</LastName>
            <ForeName>Per</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Public Health and Clinical Medicine, Umeå University, SE-901 87 Umeå, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wahlberg</LastName>
            <ForeName>Jeanette</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology and Department of Medical and Health Sciences, Linköpings University, SE-581 83 Linköping, Sweden; Department of Internal Medicine, School of Health and Medical Sciences, Örebro University, SE-702 81 Örebro, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gezelius</LastName>
            <ForeName>Anton</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Women's and Children's Health, Karolinska Institutet, Pediatric Endocrinology Unit, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kämpe</LastName>
            <ForeName>Olle</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine (Solna), Center for Molecular Medicine, Karolinska Institutet, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bensing</LastName>
            <ForeName>Sophie</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Medicine and Surgery, Karolinska Institutet and Department of Endocrinology, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lajic</LastName>
            <ForeName>Svetlana</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Women's and Children's Health, Karolinska Institutet, Pediatric Endocrinology Unit, Karolinska University Hospital, SE-171 76 Stockholm, Sweden. Electronic address: Svetlana.Lajic@ki.se.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Psychoneuroendocrinology</MedlineTA>
        <NlmUniqueID>7612148</NlmUniqueID>
        <ISSNLinking>0306-4530</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000224" MajorTopicYN="Y">Addison Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005222" MajorTopicYN="N">Mental Fatigue</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Addison’s disease</Keyword>
        <Keyword MajorTopicYN="Y">Cognition</Keyword>
        <Keyword MajorTopicYN="Y">Executive function</Keyword>
        <Keyword MajorTopicYN="Y">Mental fatigue</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>20</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35290880</ArticleId>
        <ArticleId IdType="doi">10.1016/j.psyneuen.2022.105714</ArticleId>
        <ArticleId IdType="pii">S0306-4530(22)00055-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
